International Travel and the Spread of Extended-spectrum Beta-lactamase-producing Escherichia Coli

CompletedOBSERVATIONAL
Enrollment

173

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Infection Due to Resistant Bacteria
Interventions
BEHAVIORAL

Analysing the behaviours of travellers while visiting India

For analyses surrounding the risks for acquisition comparisons between those who acquire ESBLs and those who do not, will be made using Stata version 9.0 (Stata Corp, College Station, TX). Differences in proportions among categorical data will be assessed using Fisher's exact test for pair-wise comparisons. Student T-test or Mann-Whitney U tests will be used for comparing means and medians. For all statistical comparisons a p-value \<0.05 will be deemed to represent statistical significance.

Trial Locations (1)

T2L2K8

Odessa Travel clinic, Calgary

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Johann DD Pitout

OTHER

NCT01296165 - International Travel and the Spread of Extended-spectrum Beta-lactamase-producing Escherichia Coli | Biotech Hunter | Biotech Hunter